**FibroTest-ActiTest in HCV**

**Estimating Fibrosis, Cirrhosis and Activity**

Recognized by AASLD\(^1\), EASL-ALEH\(^2\), CASL\(^3\), APASL\(^5\) and WHO\(^4\) Guidelines

---

**FibroTest-ActiTest : access to care**

FibroTest is recognized by the following guidelines for IFN-free HCV treatment access: AASLD\(^1\), EASL-ALEH\(^2\), CASL\(^3\), APASL\(^5\) and WHO\(^4\).

---

**Diagnose before treatment**

FibroTest evaluates both fibrosis in the early stages (F0 to F3)\(^15\) as well as cirrhosis (F4). Cirrhosis can be fine-tuned to 3 levels:\(^13\)

- **F4.1** (cut-off 0.74): cirrhosis without complications
- **F4.2** (cut-off 0.85): cirrhosis with oesophageal varices only
- **F4.3** (cut-off 0.95): cirrhosis with severe complications (primary liver cancer, bleeding or decompensation)

FibroTest offers the same diagnostic value regardless of ethnicity, gender, transaminases level, HCV genotype and viral load.\(^8\)

ActiTest is more accurate for the diagnosis of necroinflammatory activity than ALT transaminases.\(^9\)

---

**Follow-up after treatment**

Cured patients still need to monitor their liver fibrosis and activity, to avoid the occurrence of related medical issues\(^14\), including cirrhosis (11% after 10 years) and complications or primary liver cancer (5% after 10 years).

---

### References:

1. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C 2015
2. EASL-ALEH Guidelines. J Hepatol 2015
3. Consensus guidelines from the CASL. Can J Gastroenterol 2012
15. Poynard T et al. J Hepatol 2010

**FibroTest benchmark in direct comparisons, in intention to diagnose**\(^7\)

**FibroTest** estimates liver fibrosis:

- **F0**: no fibrosis
- **F1**: minimal fibrosis
- **F2**: moderate fibrosis
- **F3**: advanced fibrosis
- **F4**: severe fibrosis (cirrhosis)

**ActiTest** estimates necroinflammatory activity:

- **A0**: no activity
- **A1**: minimal activity
- **A2**: moderate activity
- **A3**: severe activity

---

Assays (done at local lab.): Alpha-2 macroglobulin, Haptoglobin, Apolipoprotein A1, Total bilirubin, GGT, ALT, age, sex - according to BioPredictive precautions of use (biopredictive.com)

Find all the scientific publications of BioPredictive non-invasive tests on the website: library.biopredictive.com

---

**BioPredictive S.A.**

218 Boulevard Saint-Germain

75007 PARIS - FRANCE

Tel : +33 1 84 79 23 90

contact@biopredictive.com

---

« FibroTest is more effective and less costly than liver biopsy. »

Liu S et al, Plos One 2011